Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes
- PMID: 1576282
- DOI: 10.1093/clinids/14.4.875
Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes
Abstract
We reviewed all 155 episodes of central venous catheter-associated fungemia among inpatients at the National Cancer Institute during a 10-year period. Candida species accounted for 98% of episodes. Fungemia was documented by culture of blood drawn through catheters in 50% of cases and by culture of both catheter-drawn and peripheral blood in 39%; mortality and the rate of dissemination were similar for these two groups. Four management strategies were used: catheter removal, antifungal therapy (with amphotericin B), both, or neither; indications for the use of both modes of treatment included fever, neutropenia, long-term indwelling catheterization, positive cultures of both catheter-drawn and peripheral blood, isolation of Candida tropicalis, and fungal isolation from two or more blood cultures. Disseminated fungal infection was documented in 82% of cases with these features but also in 35% of the less severe cases treated only with catheter removal. In addition, nine (82%) of 11 cases managed only with antifungal therapy had a negative outcome (either death from disseminated infection or the recurrence of fevers and/or fungemia), a finding suggesting that intravascular catheters should be removed in fungemia. Virtually all cases of catheter-associated fungemia in patients with cancer are clinically significant and require prompt therapy with amphotericin B.
Similar articles
-
Sepsis due to Rhodotorula related to use of indwelling central venous catheters.Clin Infect Dis. 1992 Apr;14(4):841-6. doi: 10.1093/clinids/14.4.841. Clin Infect Dis. 1992. PMID: 1576278
-
Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol.Support Care Cancer. 1999 Jan;7(1):39-43. doi: 10.1007/s005200050221. Support Care Cancer. 1999. PMID: 9926973
-
Candida krusei fungemia. An escalating serious infection in immunocompromised patients.Arch Intern Med. 2000 Sep 25;160(17):2659-64. doi: 10.1001/archinte.160.17.2659. Arch Intern Med. 2000. PMID: 10999981
-
Nosocomial Candida krusei fungemia in cancer patients: report of 10 cases and review.J Chemother. 1999 Apr;11(2):131-6. doi: 10.1179/joc.1999.11.2.131. J Chemother. 1999. PMID: 10326744 Review.
-
Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review.J Infect. 2005 Oct;51(3):e85-7. doi: 10.1016/j.jinf.2004.08.034. J Infect. 2005. PMID: 16230210 Review.
Cited by
-
Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997-2001).Support Care Cancer. 2006 Jan;14(1):52-5. doi: 10.1007/s00520-005-0836-1. Epub 2005 Jun 10. Support Care Cancer. 2006. PMID: 15947955
-
Invasive fungal infections in acute leukemia.Ther Adv Hematol. 2011 Aug;2(4):231-47. doi: 10.1177/2040620711410098. Ther Adv Hematol. 2011. PMID: 23556092 Free PMC article.
-
Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.Infect Immun. 2004 Oct;72(10):6023-31. doi: 10.1128/IAI.72.10.6023-6031.2004. Infect Immun. 2004. PMID: 15385506 Free PMC article.
-
Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Paediatr Drugs. 2001;3(10):733-61. doi: 10.2165/00128072-200103100-00003. Paediatr Drugs. 2001. PMID: 11706924 Review.
-
Antifungal Compounds against Candida Infections from Traditional Chinese Medicine.Biomed Res Int. 2017;2017:4614183. doi: 10.1155/2017/4614183. Epub 2017 Dec 28. Biomed Res Int. 2017. PMID: 29445739 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources